Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.50 |
| ▸ | ITGAV | P06756 | 20/20 | 0.50 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.43 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.43 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6016567 | 0.92 | ITGAV (0.44) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL6016464 | 0.84 | ITGAV (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL2231336 | 0.83 | ITGAV (0.56) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL274667 | 0.83 | ITGAV (0.50) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL2231328 | 0.83 | ITGAV (0.56) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL2231355 | 0.83 | ITGAV (0.50) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL2231350 | 0.83 | ITGAV (0.50) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL13237151 | 0.83 | ITGAV (0.51) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL2232146 | 0.83 | ITGAV (0.51) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL2232143 | 0.83 | ITGAV (0.51) | ITGB3ITGAVITGB5ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1210348-B9 | NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | AVENTIS PHARMA GMBH (DE) | 2006-04-26 | — | — | EP | claimed |
| EP-1210348-B1 | NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | AVENTIS PHARMA GMBH (DE) | 2005-09-28 | — | — | EP | claimed |
| EP-1210348-B9 | NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | AVENTIS PHARMA GMBH (DE) | 2006-04-26 | — | — | EP | disclosed |
| EP-1210348-B1 | NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | AVENTIS PHARMA GMBH (DE) | 2005-09-28 | — | — | EP | disclosed |
| US-20040198718-A1 | Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2004-10-07 | — | — | US | disclosed |
| US-6743800-B1 | VITRONECTIN RECEPTOR ANTAGONISTS AND INHIBITORS OF CELL ADHESION; OSTEOPOROSIS, ANGIOGENESIS INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-01 | — | — | US | disclosed |
| EP-1210348-A1 | NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001002398-A1 | NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-01-11 | — | — | WO | disclosed |
| EP-1065207-A1 | Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them | Aventis Pharma Deutschland GmbH (DE) | 2001-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198718-A1 | Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them | VCAM1, ADGRF1, ADGRE5 | ITGB3 83/4885ITGAV 181/4885ITGB5 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.